Short Interest in Dyadic International, Inc. (NASDAQ:DYAI) Declines By 19.9%

Dyadic International, Inc. (NASDAQ:DYAI) was the recipient of a large decrease in short interest during the month of February. As of February 28th, there was short interest totalling 96,600 shares, a decrease of 19.9% from the February 13th total of 120,600 shares. Based on an average daily trading volume, of 90,700 shares, the short-interest ratio is presently 1.1 days. Currently, 0.5% of the shares of the stock are short sold.

Dyadic International Price Performance

Shares of NASDAQ:DYAI opened at $1.38 on Monday. The company’s fifty day moving average price is $1.53 and its 200-day moving average price is $1.42. The firm has a market capitalization of $40.83 million, a price-to-earnings ratio of -6.00 and a beta of 0.95. Dyadic International has a one year low of $0.93 and a one year high of $2.67. The company has a debt-to-equity ratio of 1.54, a current ratio of 5.15 and a quick ratio of 5.15.

Hedge Funds Weigh In On Dyadic International

Institutional investors have recently made changes to their positions in the stock. Truist Financial Corp bought a new position in shares of Dyadic International in the 4th quarter worth $428,000. Inlet Private Wealth LLC bought a new position in shares of Dyadic International in the 4th quarter worth $52,000. Bank of America Corp DE increased its holdings in shares of Dyadic International by 16,146.7% in the 4th quarter. Bank of America Corp DE now owns 27,132 shares of the biotechnology company’s stock worth $47,000 after buying an additional 26,965 shares during the last quarter. Millennium Management LLC bought a new position in shares of Dyadic International during the 4th quarter valued at $28,000. Finally, Jane Street Group LLC bought a new position in shares of Dyadic International during the 4th quarter valued at $45,000. Institutional investors own 27.95% of the company’s stock.

About Dyadic International

Dyadic International, Inc, a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health.